Efficient transport into white blood cells
AssigneeXigen SA
InventorChristophe Bonny
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of specific transporter cargo conjugate molecules for the transport of a substance of interest (cargo molecule) into white blood cells. Said transporter cargo conjugate molecules may be used for the treatment, prophylaxis, attenuation and/or amelioration of a disease and/or disorder involving white blood cells. The present invention also relates to manufacture of said transporter cargo conjugate molecules, to a method of transporting a substance of interest (cargo) into a white blood cell and to a white blood cell comprising said transporter cargo conjugate molecules or fragments thereof.
Claims23
A method of treatment, prophylaxis, attenuation and/or amelioration of a disease and/or disorder involving white blood cells, the method comprising administering to a subject in need thereof a transporter cargo conjugate molecule comprising:
- a) as component (A):
- a (poly-)peptide comprising the amino acid sequence of HIV TAT residues 49 to 57 (SEQ ID NO:
- 2), or a variant thereof,
- b) as component (B):
- a pharmaceutically active cargo molecule, and
- wherein the variant of SEQ ID NO:2 is selected from the group consisting of:
- i) a peptide comprising at least one amino acid sequence according to SEQ ID NO:
- 235, or reverse sequence thereof, and
- ii) a peptide comprising at least one amino acid sequence according to any one of SEQ ID NOs:
- 2 to 116, or reverse sequence thereof.
A method of transporting a substance of interest (cargo molecule) into white blood cells, the method comprising contacting the white blood cells with a transporter cargo conjugate molecule, wherein the transporter cargo conjugate molecule comprises:
- a) as component (A):
- a peptide comprising the amino acid sequence of HIV TAT residues 49 to 57 (SEQ ID NO:
- 2), or a variant thereof,
- b) as component (B):
- a cargo molecule, and
- wherein the variant of SEQ ID NO:2 is selected from the group consisting of:
- i) a peptide comprising at least one amino acid sequence according to SEQ ID NO:
- 235, or reverse sequence thereof, and
- ii) a peptide comprising at least one amino acid sequence according to any one of SEQ ID NOs:
- 2 to 116, or reverse sequence thereof.
(canceled)
19-20. (canceled)
24-25. (canceled)
Dependencies are inferred from the claim text.